TEL AVIV, Israel I March 9, 2015 I Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed”), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today the beginning of enrollment in its Phase IIb clinical trial, or our ARREST Study, of aramchol in patients with Non-Alcoholic Steato-Hepatitis, or NASH, who also suffer from obesity and insulin resistance.
Galmed has commenced its multinational ARREST Study of aramchol, which is expected to take place in more than 70 centers in 12 countries, including the United States. Dr. Maya Halpern, Galmed’s Chief Medical Officer, commented, “We are pleased that Professor Vlad Ratziu, from the University Pierre et Marie Curie in Paris, an internationally acclaimed key opinion leader, is the ARREST Study’s global principal investigator, and Professor Rohit Loomba, from the University of California San Diego School of Medicine, is the ARREST Study’s U.S.-based principal investigator.”
Galmed’s ARREST Study is a multi-center, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb clinical trial of aramchol. The trial’s primary end-point is a statistically significant reduction of liver fat content measured by Magnetic Resonance Spectroscopy, or MRS, and the trial’s secondary end-point is the complete resolution of NASH, as measured by two biopsies (at the beginning and at the end of the ARREST Study), and improvement of the NAFLD Activity Score (NAS), as well as an improvement in the markers of liver inflammation and various metabolic biomarkers.
In addition, Galmed today announced that it has also expanded its clinical activities to include patient recruitment for the ARREST Study in the United States. Allen Baharaff, Galmed’s Chief Executive Officer, stated, “We believe that U.S.-based patient recruitment will shorten the recruitment time for our ARREST Study, as well as improve the study’s breadth and relevance.” Galmed currently expects to release interim results of the ARREST Study in the first half of 2016, later than originally planned, due to our revised geographic strategy of enrollment on the Study. Galmed further reaffirmed that it expects to release top-line data by the end of 2016.
Mr. Baharaff concluded, “While the alignment and coordination of the study’s geographic expansion caused a slight delay, we believe we’re much better off for adding robust clinical operations in the United States and look forward to the interim results.”
About Galmed
Galmed is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need.
SOURCE: Galmed Pharmaceuticals
Post Views: 88
TEL AVIV, Israel I March 9, 2015 I Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed”), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today the beginning of enrollment in its Phase IIb clinical trial, or our ARREST Study, of aramchol in patients with Non-Alcoholic Steato-Hepatitis, or NASH, who also suffer from obesity and insulin resistance.
Galmed has commenced its multinational ARREST Study of aramchol, which is expected to take place in more than 70 centers in 12 countries, including the United States. Dr. Maya Halpern, Galmed’s Chief Medical Officer, commented, “We are pleased that Professor Vlad Ratziu, from the University Pierre et Marie Curie in Paris, an internationally acclaimed key opinion leader, is the ARREST Study’s global principal investigator, and Professor Rohit Loomba, from the University of California San Diego School of Medicine, is the ARREST Study’s U.S.-based principal investigator.”
Galmed’s ARREST Study is a multi-center, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb clinical trial of aramchol. The trial’s primary end-point is a statistically significant reduction of liver fat content measured by Magnetic Resonance Spectroscopy, or MRS, and the trial’s secondary end-point is the complete resolution of NASH, as measured by two biopsies (at the beginning and at the end of the ARREST Study), and improvement of the NAFLD Activity Score (NAS), as well as an improvement in the markers of liver inflammation and various metabolic biomarkers.
In addition, Galmed today announced that it has also expanded its clinical activities to include patient recruitment for the ARREST Study in the United States. Allen Baharaff, Galmed’s Chief Executive Officer, stated, “We believe that U.S.-based patient recruitment will shorten the recruitment time for our ARREST Study, as well as improve the study’s breadth and relevance.” Galmed currently expects to release interim results of the ARREST Study in the first half of 2016, later than originally planned, due to our revised geographic strategy of enrollment on the Study. Galmed further reaffirmed that it expects to release top-line data by the end of 2016.
Mr. Baharaff concluded, “While the alignment and coordination of the study’s geographic expansion caused a slight delay, we believe we’re much better off for adding robust clinical operations in the United States and look forward to the interim results.”
About Galmed
Galmed is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need.
SOURCE: Galmed Pharmaceuticals
Post Views: 88
